Dr. Babar Bashir
Claim this profileThomas Jefferson University Hospital
Studies Pancreatic Cancer
Studies Cancer
14 reported clinical trials
28 drugs studied
Area of expertise
1Pancreatic Cancer
Stage IV
Stage III
RECIST
2Cancer
Stage IV
Stage III
BRCA positive
Affiliated Hospitals
Clinical Trials Babar Bashir is currently running
ARTS-021
for Advanced Cancer
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).
Recruiting1 award Phase 1 & 2
Ipatasertib + Chemotherapy
for Cancer
This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced) or from where it first started (primary site) to other places in the body (metastatic), and has PTEN and AKT genetic changes. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Targeted therapy, such as Ipatasertib, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of ipatasertib to paclitaxel in solid tumors with PTEN and AKT genetic changes could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression). Researchers hope to learn if paclitaxel plus ipatasertib will shrink this type of cancer or stop its growth.
Recruiting1 award Phase 2
More about Babar Bashir
Clinical Trial Related2 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Babar Bashir has experience with
- LYL797
- Ad5.F35-hGCC-PADRE
- Nivolumab
- BT5528
- ELU001
- ARTS-021
Breakdown of trials Babar Bashir has run
Pancreatic Cancer
Cancer
Solid Tumors
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Babar Bashir specialize in?
Babar Bashir focuses on Pancreatic Cancer and Cancer. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are Stage III.
Is Babar Bashir currently recruiting for clinical trials?
Yes, Babar Bashir is currently recruiting for 4 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Babar Bashir has studied deeply?
Yes, Babar Bashir has studied treatments such as LYL797, Ad5.F35-hGCC-PADRE, Nivolumab.
What is the best way to schedule an appointment with Babar Bashir?
Apply for one of the trials that Babar Bashir is conducting.
What is the office address of Babar Bashir?
The office of Babar Bashir is located at: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 19107 United States. This is the address for their practice at the Thomas Jefferson University Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.